Welcome to our dedicated page for Biolargo SEC filings (Ticker: BLGO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The BioLargo, Inc. (OTCQX: BLGO) SEC filings page on Stock Titan provides access to the company’s official reports and current disclosures as filed with the U.S. Securities and Exchange Commission. These documents include Form 8-K current reports describing material events such as contract terminations, legal actions, investor presentations, and equity-related transactions, as well as other periodic and annual filings available through EDGAR.
For a cleantech and life sciences company like BioLargo, SEC filings offer detail on its technology portfolio, licensing and manufacturing agreements, and capital structure that may not appear in press releases alone. Recent 8-K filings, for example, describe the termination of a license and preferred master manufacturing agreement related to pet odor control products, potential impairment of a note receivable, and the filing of a federal lawsuit to protect patented CupriDyne odor control technology. Other 8-Ks discuss investor presentation materials for events such as LD Micro and NobleCon, and the conversion of unpaid salary and expenses by officers into locked-up common stock.
Through this page, users can review BioLargo’s disclosures about material agreements, legal proceedings, financial considerations tied to specific contracts, and corporate actions involving its common stock. Stock Titan enhances this access with AI-powered summaries that help explain the significance of complex filings, including key points from Form 8-K reports and other documents. Real-time updates from EDGAR, combined with AI-generated highlights, make it easier to track how BioLargo reports on its environmental technologies, medical subsidiaries, licensing relationships, and governance matters over time.
BioLargo, Inc. filed a current report announcing that CEO Dennis P. Calvert will participate in a shareholder town hall meeting on May 5, 2026 at 1:00 PM Pacific Time, hosted on the BioLargo Shareholder Community Discord channel.
The town hall will feature a brief company update followed by a Q&A session with shareholders. The meeting will be recorded and a transcript will be filed on Form 8‑K prior to the market open the next day. The company also includes standard forward-looking statement and Safe Harbor language referencing risks described in its most recent SEC filings.
BioLargo, Inc. files an amendment to its 2025 annual report to add the Part III disclosures it had planned to provide via a proxy statement. The amendment leaves all previously reported financial statements unchanged.
The filing details board composition, committee membership and governance practices, noting four independent directors and combined CEO/Chairman roles. It describes executive employment agreements, with base salaries of $288,603 for both the CEO and Chief Science Officer and option-based compensation for the CFO and other executives.
BioLargo reports that directors are paid quarterly retainers entirely in stock options instead of cash, and that all Section 16 reports were timely except for one option grant to the CFO. The filing shows insiders collectively owning 19.3% of common stock as of April 30, 2026, outlines related‑party investments by the CEO in subsidiary Clyra Medical notes guaranteed by BioLargo, and discloses 2025 audit fees of $117,000 plus $9,000 in audit‑related services.
BioLargo, Inc. registers 31,730,651 shares of common stock for resale by selling stockholders; these shares are issuable upon exercise of warrants issued between April 16, 2021 and January 6, 2026. The company is not selling any shares here and will receive no proceeds from secondary sales; however, it may receive up to $8,416,462 if the warrants are exercised in full at a weighted average exercise price of $0.265 per share. Shares outstanding were 320,474,620 as of the prospectus date; assuming full exercise the post-issuance total would be 352,205,271 shares. Exercise prices range from $0.19 to $0.33, and certain warrants may be callable if the registration is effective and the market price meets the stated threshold.
BioLargo, Inc. registers 30,000,000 shares of common stock for resale by a selling stockholder under a registration statement filed pursuant to Rule 424(b)(4). The shares are reserved for issuance to Clearthink Capital Partners under a March 20, 2026 Purchase Agreement and related Registration Rights Agreement.
The Purchase Agreement contemplates up to $10,000,000 of purchases by Clearthink at a price equal to the average of the two lowest daily closing prices during the eight trading days preceding each purchase; the company will not receive proceeds from resales by Clearthink under this prospectus, though it may receive proceeds up to the $10,000,000 Commitment Amount if it directs sales to Clearthink consistent with the agreement. The Purchase Agreement contains a 9.99% Beneficial Ownership Cap and other customary terms; timing and amounts of any sales are within the parties' contractual mechanics.
BioLargo, Inc. is registering up to 31,730,651 shares of common stock for resale by existing warrant holders. The shares will be issued if investors exercise warrants that were sold between April 2021 and January 2026 at a weighted average price of $0.265 per share.
BioLargo will not sell any shares in this offering and will receive no proceeds from stockholder resales, but could receive up to $8.42 million in gross proceeds if all warrants are exercised. As of the prospectus date, the company had 320,474,620 shares outstanding, which would increase to 352,205,271 shares if all registered warrant shares are issued.
The company focuses on cleantech solutions including PFAS water treatment, industrial odor and VOC control, and a liquid-sodium battery platform. It reports recurring losses, substantial cash needs, a going-concern warning, heavy reliance on external financing, and material litigation tied to a former major private‑label odor-control customer.
BioLargo, Inc. filed an S-1 registering up to 30,000,000 shares of common stock for resale by Clearthink Capital Partners under an equity purchase agreement. BioLargo may sell shares to Clearthink over time and receive up to $10,000,000 in gross proceeds, while Clearthink resells the shares to the public.
The company had 320,474,620 shares outstanding as of the prospectus date, which would rise to 350,474,620 shares if all 30,000,000 shares are issued. The agreement includes a 9.99% beneficial ownership cap, and Clearthink is deemed an underwriter. BioLargo highlights significant risks, including ongoing Pooph litigation, a $15.2 million net loss in 2025, substantial cash use, going-concern doubts, reliance on external financings, and thin, penny-stock trading on the OTCQX Best Market.
BIOLARGO, INC. Chief Science Officer Kenneth Reay Code received a grant of 69,444 shares of common stock at an acquisition price of $0.162 per share. The award was issued in exchange for reduced salary and unreimbursed business expenses.
The shares are subject to a lock-up agreement and cannot be sold until the company reports at least $40 million in gross revenue for any quarter or year, or its market capitalization exceeds $300 million, or there is a change in control. Following this grant, his total holdings are 25,875,752 shares, including 22,139,012 shares held indirectly through a wholly owned corporation.
BIOLARGO, INC. director Jack B. Strommen received an option grant as compensation for board service. He was awarded an Option to Purchase Common Stock covering 92,593 shares at an exercise price of $0.162 per share, with no cash paid for the grant itself.
The option was issued in lieu of $15,000 in director fees for the most recently completed quarter under the company’s 2024 Equity Incentive Plan. Following this grant, Strommen directly holds derivative securities representing 2,452,103 underlying shares, and this option is scheduled to expire on March 31, 2036.